Voxzogo demonstrates positive results for infants with dwarfism
![Photo: LUKAS BARTH/REUTERS / X03379](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14143574.ece/ALTERNATES/schema-16_9/doc7lfhhreein51ae6ol74p.jpg)
In November 2021, the US Food and Drug Administration (FDA) market approved Biomarin’s drug, Voxzogo (vosoritide), for five-year-old children and up who have achondroplasia, also known as dwarfism.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Biomarin raises Voxzogo sales expectations again
For subscribers
Biomarin projects 2022 Voxzogo sales of USD 115m
For subscribers
Ascendis Pharma initiates clinical trial of dwarfism drug
For subscribers